Anixa Biosciences (NASDAQ:ANIX) Announces Earnings Results

Anixa Biosciences (NASDAQ:ANIX) issued its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08), FiscalAI reports.

Anixa Biosciences Price Performance

ANIX stock opened at $2.75 on Friday. The company’s 50-day moving average is $3.34 and its 200-day moving average is $2.99. The stock has a market capitalization of $93.56 million, a PE ratio of -8.59 and a beta of 0.51. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANIX. NewEdge Advisors LLC acquired a new stake in Anixa Biosciences in the second quarter valued at approximately $33,000. Cetera Investment Advisers acquired a new position in shares of Anixa Biosciences during the fourth quarter worth approximately $35,000. Northwestern Mutual Wealth Management Co. raised its position in shares of Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. bought a new position in shares of Anixa Biosciences in the 2nd quarter worth $37,000. Finally, Millennium Management LLC bought a new position in shares of Anixa Biosciences in the 4th quarter worth $38,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ANIX. Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.00.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.